Latest / AI Investment Edge: Stocks, Markets & Money / EP 36 | GSK Stock Analysis: Can New Drugs Beat the Patent Cliff?
Transcript
- 0:00SPEAKER_00: You know,
- 0:00SPEAKER_00: if you watch like a track and field relay race,
- 0:03SPEAKER_00: the most dangerous anxiety inducing moment,
- 0:07SPEAKER_00: it isn't when the runners are in a full sprint.
- 0:09SPEAKER_01: Right.
- 0:10SPEAKER_01: It's the handoff.
- 0:11SPEAKER_00: Exactly.
- 0:11SPEAKER_00: The baton pass.
- 0:13SPEAKER_00: You have one runner who is absolutely exhausted.
- 0:15SPEAKER_00: I mean, lungs burning,
- 0:17SPEAKER_00: but still pushing at maximum speed,
- 0:19SPEAKER_00: trying to hand off to a new runner who is just barely accelerating.
- 0:23SPEAKER_01: And if you drop that baton, the race is over.
- 0:24SPEAKER_01: It doesn't matter how fast everyone is.
- 0:26SPEAKER_00: Yeah, you lose.
- 0:28SPEAKER_00: Which brings us to today's deep dive.
- 0:30SPEAKER_00: Welcome in, everyone.
- 0:31SPEAKER_00: Today, we're pulling from a really fascinating source,
- 0:34SPEAKER_00: AI Investment Edge,
- 0:36SPEAKER_00: to look at what might be one of
- 0:38SPEAKER_00: the highest stakes funding relay races happening right now.
- 0:42SPEAKER_01: It's a massive dilemma.
- 0:43SPEAKER_00: It really is.
- 0:44SPEAKER_00: The core investment dilemma we're unpacking for you today is this.
- 0:48SPEAKER_00: Can today's highly profitable patented drugs actually generate enough cash
- 0:53SPEAKER_00: to fund tomorrow's replacements before those old patents expire?
- 0:57SPEAKER_00: And we're looking at GSK.
- 0:59SPEAKER_01: And to frame this correctly right out of the gate,
- 1:01SPEAKER_01: we need to remember that patent protection and generic erosion,
- 1:05SPEAKER_01: they vary medicine by medicine.
- 1:07SPEAKER_00: Right.
- 1:07SPEAKER_00: It's not all at once.
- 1:08SPEAKER_01: Exactly.
- 1:09SPEAKER_01: There's no uniform, say,
- 1:11SPEAKER_01: five-year reinvention cycle where
- 1:12SPEAKER_01: a company's entire revenue just vanishes overnight.
- 1:16SPEAKER_01: The runners on this track, they hand off at completely different times.
- 1:20SPEAKER_00: So let's give you all a short, plain business introduction just to ground this.
- 1:25SPEAKER_00: GSK is a British global biopharmaceutical company.
- 1:28SPEAKER_00: If you're trying to picture what they actually make,
- 1:31SPEAKER_00: their focus is on prescription specialty medicines.
- 1:33SPEAKER_01: Which means major HIV treatments, right?
- 1:36SPEAKER_00: Right.
- 1:37SPEAKER_01: Through their Vive Healthcare division.
- 1:38SPEAKER_00: Right, exactly.
- 1:40SPEAKER_00: And respiratory medicines like Trilogy and Nucala, plus oncology drugs.
- 1:45SPEAKER_00: And they also have this massive vaccines division.
- 1:47SPEAKER_00: You've probably heard of the shingles vaccine, Shingrix, that alongside general medicines.
- 1:53SPEAKER_01: And just to clear up a very,
- 1:54SPEAKER_01: very common misconception,
- 1:56SPEAKER_01: GSK spun off its consumer healthcare division into
- 1:59SPEAKER_01: a completely separate company called Halion.
- 2:01SPEAKER_00: Yeah, that's a big one.
- 2:02SPEAKER_01: So if you are picturing toothpaste or like over-the-counter painkillers,
- 2:06SPEAKER_01: GSK is not today's owner of that old consumer products business.
- 2:10SPEAKER_01: What they own today is entirely shaped by scientific patents,
- 2:14SPEAKER_01: clinical evidence, regulatory approvals, and payer access.
- 2:17SPEAKER_00: Okay, before we get into the really heavy financial mechanics, I need to play the accuracy card.
- 2:23SPEAKER_00: We have to be incredibly precise about what asset we're actually discussing
- 2:27SPEAKER_00: so you don't get confused looking at your own screens.
- 2:29SPEAKER_01: Definitely necessary here.
- 2:31SPEAKER_00: Yep.
- 2:31SPEAKER_00: We are covering the London ordinary share quoted in Pence Sterling.
- 2:35SPEAKER_00: So looking at the latest 30 October close,
- 2:38SPEAKER_00: we are talking about exactly 18 pounds and 55 pence per ordinary share.
- 2:43SPEAKER_01: And that is a dated close, right?
- 2:44SPEAKER_01: Not a live Sunday quote.
- 2:46SPEAKER_00: Exactly.
- 2:46SPEAKER_01: And you must not mix this up with the USADS that traded in New York.
- 2:51SPEAKER_01: One USADS actually represents two ordinary shares.
- 2:54SPEAKER_01: So that dollar price is a completely different metric from
- 2:57SPEAKER_01: the London pence dividends or earnings we're breaking down today.
- 3:00SPEAKER_00: Right.
- 3:00SPEAKER_00: Don't mix those up.
- 3:02SPEAKER_00: So our AI Investment Edge research looks at this company
- 3:04SPEAKER_00: through four distinct financial synthesis lenses.
- 3:08SPEAKER_00: We've got earnings quality,
- 3:09SPEAKER_00: mix and margins,
- 3:11SPEAKER_00: acquisition debt, and scientific investment beyond just factory spending.
- 3:15SPEAKER_01: A lot to cover.
- 3:16SPEAKER_00: Yeah.
- 3:17SPEAKER_00: So I want to start with earnings quality,
- 3:19SPEAKER_00: keeping in mind the Q3 results that were already released back on 28 October.
- 3:24SPEAKER_01: Right.
- 3:24SPEAKER_01: So the top line sales for Q3 looks solid.
- 3:27SPEAKER_01: 8.89 billion pounds.
- 3:29SPEAKER_01: That's up 4% at actual exchange rates and up 5% at constant currency.
- 3:34SPEAKER_00: Okay.
- 3:34SPEAKER_00: 5% is solid.
- 3:36SPEAKER_01: It is.
- 3:36SPEAKER_01: But when you look at the basic earnings per ordinary share,
- 3:39SPEAKER_01: the total or IFRS EPS, it was 38.5 pence.
- 3:45SPEAKER_01: That is down 23% at actual rates.
- 3:48SPEAKER_00: Wait, pause right there.
- 3:49SPEAKER_00: They are selling 5% more medicine in constant currency, but the total EPS dropped 23%.
- 3:55SPEAKER_00: I mean, how does a company sell more product but make that much less per share?
- 4:02SPEAKER_01: I know, it feels like a massive contradiction.
- 4:04SPEAKER_01: Until you look at the core EPS,
- 4:06SPEAKER_01: which was 54.6 pence,
- 4:09SPEAKER_01: that was down just 1% at actual rates, and actually up 1% at constant currency.
- 4:15SPEAKER_00: Oh, okay.
- 4:16SPEAKER_01: In fact, core operating profit rose 3% at actual rates.
- 4:20SPEAKER_01: So the massive gap between that plunging total EPS and
- 4:23SPEAKER_01: the stable core EPS reflects what the company defines as specified adjusting items.
- 4:27SPEAKER_01: We're talking about relevant acquisition costs, restructuring and impairment adjustments.
- 4:33SPEAKER_00: So basically the business of selling Madison is stable,
- 4:36SPEAKER_00: but the cost of rearranging the business is just dragging down
- 4:39SPEAKER_00: the headline earnings.
- 4:40SPEAKER_01: Yes, but and here is a crucial distinction we cannot ignore.
- 4:44SPEAKER_01: Normal research expense and financing costs affect both total and core earnings.
- 4:49SPEAKER_00: They aren't separated out?
- 4:51SPEAKER_01: No, they are not just accounting tricks buried in the reconciliation between the two numbers.
- 4:55SPEAKER_01: For instance, core R&D actually rose 22% at constant currency.
- 5:00SPEAKER_00: Wow.
- 5:01SPEAKER_00: So we shouldn't just look at the reported EPS dropping and assume,
- 5:04SPEAKER_00: like, patient demand is collapsing.
- 5:06SPEAKER_00: They are actively choosing to spend significantly more on research.
- 5:10SPEAKER_01: Exactly.
- 5:11SPEAKER_01: Which leads us directly into our second lens, mix and margins.
- 5:15SPEAKER_01: Because to fund a 22% jump in research without cratering your profit,
- 5:19SPEAKER_01: you need incredibly strong margins.
- 5:21SPEAKER_00: Makes sense.
- 5:22SPEAKER_00: So what was the margin?
- 5:24SPEAKER_01: The Q3 core operating margin was 34.6%,
- 5:27SPEAKER_01: which is nearly flat, down just 0.3 percentage points at actual exchange rates.
- 5:33SPEAKER_01: They achieved this because specialty medicines grew a massive 15% at constant currency.
- 5:38SPEAKER_00: And that balances out the weaker areas, I'm guessing.
- 5:41SPEAKER_01: Right.
- 5:41SPEAKER_01: It balanced out a 2% fall in vaccines and flat general medicines.
- 5:45SPEAKER_00: Okay.
- 5:46SPEAKER_00: So a richer mix of complex specialty drugs keeps the margins high.
- 5:50SPEAKER_00: But they're also trying to, you know, manufacture cash through cost control.
- 5:55SPEAKER_00: The source highlights this Accelerate Growth Initiative.
- 5:59SPEAKER_01: Yes.
- 6:00SPEAKER_00: Targeting 1.90 billion pounds of annual savings by 2029.
- 6:04SPEAKER_00: Sounds great on the slide deck, but are we actually seeing real cash saved today?
- 6:09SPEAKER_00: Yes.
- 6:10SPEAKER_01: We have to be very careful with corporate target language here.
- 6:13SPEAKER_01: The estimated total program cost to achieve those future savings is £2.40 billion,
- 6:17SPEAKER_01: including £2.10 billion in cash costs.
- 6:19SPEAKER_01: In Q3 alone, they took an expense of £328 million for this program.
- 6:23SPEAKER_01: And I saw that £318 million of that was classified as a cash charge?
- 6:33SPEAKER_01: It was classified as a cash charge,
- 6:34SPEAKER_01: yes, with 10 million as non-cash, but that is simply an accounting classification.
- 6:40SPEAKER_01: It does not prove that 318 million pounds was actually paid out in physical cash
- 6:44SPEAKER_01: during that exact quarter.
- 6:45SPEAKER_00: So it's more of a paper hit right now.
- 6:47SPEAKER_01: Exactly.
- 6:49SPEAKER_01: Management even noted that 2026 program accounting charges could reach £1 billion,
- 6:54SPEAKER_01: with the actual cash effects bleeding into the following year.
- 6:57SPEAKER_01: Got it.
- 6:58SPEAKER_01: You can never call that expense savings,
- 7:00SPEAKER_01: and you certainly shouldn't assume the future 2029 savings are already achieved.
- 7:05SPEAKER_01: Furthermore,
- 7:06SPEAKER_01: the savings they do eventually capture are mostly slated to be reinvested into R&D,
- 7:11SPEAKER_01: not passed straight through to near-term earnings.
- 7:14SPEAKER_00: Okay, so let's ground all this theoretical future spending in cold historical valuation.
- 7:19SPEAKER_00: How do we value this based purely on actual completed numbers?
- 7:23SPEAKER_01: If we look at the actual completed financial year 2025,
- 7:27SPEAKER_01: total basic EPS was 141.1 pence and core basic EPS was 172 pence.
- 7:34SPEAKER_01: Dividing our share price of 18.55 pounds by those actuals gives us historical P.E.
- 7:40SPEAKER_01: multiples of 13.15 times on the total and 10.78 times on the core.
- 7:46SPEAKER_00: And we need to emphasize for anyone building a model at home right now,
- 7:50SPEAKER_00: neither of those is an expected or forward multiple.
- 7:52SPEAKER_00: They are purely historical realities.
- 7:54SPEAKER_01: Completely historical.
- 7:56SPEAKER_00: Yep.
- 7:56SPEAKER_00: Let's explore those third and fourth financial lenses,
- 7:59SPEAKER_00: acquisition debt and scientific investment.
- 8:02SPEAKER_00: Think about that toll bridge analogy.
- 8:04SPEAKER_00: GSK is essentially tasked with building the next massive span of a bridge,
- 8:08SPEAKER_00: while traffic is still driving and paying tolls on the current span.
- 8:12SPEAKER_01: Building that new span is incredibly capital intensive.
- 8:15SPEAKER_01: And we aren't just talking about pouring concrete for new factories, you know.
- 8:19SPEAKER_01: For the first nine months, purchases of property and equipment were 0.92 billion pounds.
- 8:25SPEAKER_01: And intangible assets were 0.71 billion pounds.
- 8:28SPEAKER_01: That is 1.63 billion combined.
- 8:31SPEAKER_01: But core R&D expense was a staggering 5.09 billion pounds.
- 8:36SPEAKER_00: I want to make sure we don't double count that penalty, though.
- 8:38SPEAKER_00: That $5 billion in research expense is already factored into their operating costs
- 8:42SPEAKER_00: and operating cash generation, right?
- 8:44SPEAKER_01: Yes, absolutely.
- 8:45SPEAKER_01: You never subtracted a second time from the company free cash flow.
- 8:49SPEAKER_00: A vital point for modelers.
- 8:50SPEAKER_00: But beyond internal R&D, they're buying entire companies to bolt on to that new bridge span.
- 8:56SPEAKER_01: They are.
- 8:56SPEAKER_01: September net debt rose to 20.74 billion pounds,
- 8:59SPEAKER_01: which is up significantly from 14.45 billion at the previous December year end.
- 9:05SPEAKER_01: This was largely driven by acquisitions.
- 9:07SPEAKER_00: Right.
- 9:07SPEAKER_00: Like the Newfoundland acquisition, which consumed 7.14 billion pounds in net cash.
- 9:12SPEAKER_01: Yes.
- 9:12SPEAKER_01: Out of 9.25 billion in total nine month business purchases.
- 9:17SPEAKER_01: And here is where the timing gap in our relay race gets incredibly dangerous.
- 9:22SPEAKER_00: The interest.
- 9:23SPEAKER_01: Exactly.
- 9:24SPEAKER_01: Borrowing and interest costs begin long
- 9:26SPEAKER_01: before those acquired medicines produce substantial sales.
- 9:29SPEAKER_01: For example,
- 9:29SPEAKER_01: the Nuvalent-related interest was expected to be around £160 million in 2026 and
- 9:35SPEAKER_01: over £300 million in 2027.
- 9:38SPEAKER_01: Meanwhile, Q3 sales of the newly acquired drug Juditro were only £3 million.
- 9:44SPEAKER_00: Wow.
- 9:44SPEAKER_00: The interest payments start sprinting immediately,
- 9:47SPEAKER_00: while the new revenue is still, like, tying its shoes.
- 9:50SPEAKER_00: So walk me through the cash.
- 9:52SPEAKER_00: I need to know the money is actually there to survive this timing gap.
- 9:55SPEAKER_00: Give me the numeric bridge for the first nine months.
- 9:59SPEAKER_01: Sure.
- 10:00SPEAKER_01: So cash generated from operations was 7.38 billion pounds pre-tax.
- 10:04SPEAKER_01: After taxes, net operating cash was 6.64 billion.
- 10:09SPEAKER_01: Now, the company defined free cash flow was reported at 4.89 billion.
- 10:14SPEAKER_00: But why not just use that 4.89 billion number?
- 10:17SPEAKER_00: The source mentions it includes disposal proceeds and
- 10:20SPEAKER_00: a special one-off VIV ownership transaction.
- 10:24SPEAKER_01: Because of those one-offs, it is not a clean recurring run rate.
- 10:28SPEAKER_01: To find a true trailing 12-month company free cash flow
- 10:32SPEAKER_01: without double counting any seasons, we use a specific formula.
- 10:36SPEAKER_00: Okay, lay it out for us.
- 10:38SPEAKER_01: We take the full year 2025 company FCF of 4.03 billion pounds.
- 10:43SPEAKER_01: We subtract the first nine months of 2025, which was 3.07 billion.
- 10:48SPEAKER_01: Then we add the new first nine months of 2026, which is that 4.89 billion.
- 10:54SPEAKER_00: I see.
- 10:54SPEAKER_00: That ensures every single quarter is counted exactly once.
- 10:57SPEAKER_01: Exactly.
- 10:58SPEAKER_01: Got it.
- 10:58SPEAKER_01: The result is a trailing 12-month FCF of 5.85 billion pounds.
- 11:04SPEAKER_00: That makes a lot of sense.
- 11:05SPEAKER_00: You have to strip out the overlapping history to see the real 12-month cycle.
- 11:10SPEAKER_00: Let's get into the actual billions of pounds moving in and out of the bank.
- 11:13SPEAKER_00: Give us the cash bridge net of overdrafts.
- 11:16SPEAKER_01: We start with an opening balance of 3.21 billion.
- 11:20SPEAKER_01: You add a .04 accounting transition adjustment, though, no, that is not actually cash earned.
- 11:27SPEAKER_01: You add the 6.64 net operating cash.
- 11:30SPEAKER_01: Then you subtract 9.96 and invest in cash.
- 11:33SPEAKER_00: Wait, pause there.
- 11:35SPEAKER_00: They brought in 6.64 billion for the drugs operating on the market right now,
- 11:40SPEAKER_00: but they spent 9.96 billion investing in the future,
- 11:44SPEAKER_00: which includes those massive acquisitions, I assume.
- 11:47SPEAKER_01: It does.
- 11:47SPEAKER_00: So they are literally...
- 11:49SPEAKER_00: Spending more on the future than the present is yielding.
- 11:52SPEAKER_01: Which requires external funding.
- 11:54SPEAKER_00: So to continue the bridge, you add 2.79 in financing cash and subtract 0.04 in currency effects.
- 12:02SPEAKER_00: That brings you to an ending net cash figure of about 2.68 billion pounds.
- 12:07SPEAKER_01: Okay.
- 12:08SPEAKER_01: Keep in mind,
- 12:09SPEAKER_01: gross cash was 2.93 billion,
- 12:11SPEAKER_01: but that differs from our 2.68 net figure because of 0.25 billion
- 12:16SPEAKER_01: in bank overdrafts.
- 12:17SPEAKER_00: Let's look closer at that $2.79 billion in financing cash.
- 12:21SPEAKER_00: A casual observer might think they only borrowed $2.79 billion.
- 12:25SPEAKER_01: No, we must explicitly call it net financing cash after offsetting payments.
- 12:30SPEAKER_01: It is a net category.
- 12:32SPEAKER_01: They actually issued new long term notes of $7.78 billion.
- 12:36SPEAKER_00: Massive.
- 12:36SPEAKER_01: Yeah, but that massive inflow was offset by debt repayments,
- 12:40SPEAKER_01: $2.05 billion in shareholder dividends, and treasury share purchases.
- 12:46SPEAKER_00: So they're generating billions in operating cash,
- 12:49SPEAKER_00: but because they are rebuilding the pipeline so aggressively,
- 12:52SPEAKER_00: net debt is rising and net cash is falling.
- 12:55SPEAKER_00: With all that turbulence, what does the timeline for an investor actually look like?
- 13:00SPEAKER_01: Well, the AI Investment Edge expert-weighted base paths are fixed
- 13:03SPEAKER_01: to two highly specific dates, 18 September 2027 and 18 September 2031.
- 13:10SPEAKER_01: They never roll forward.
- 13:11SPEAKER_00: Fixed dates.
- 13:12SPEAKER_00: Got it.
- 13:12SPEAKER_01: Based on our 18.55 pound price,
- 13:15SPEAKER_01: the targets imply cumulative price gains of 10.79% for the first horizon and 42.86%
- 13:22SPEAKER_01: for the second.
- 13:24SPEAKER_01: Note that those are cumulative, not annualized gains.
- 13:27SPEAKER_00: And the ratings tied to those horizons?
- 13:29SPEAKER_01: Currently weighted as a strong buy for the first horizon and a buy for
- 13:32SPEAKER_01: the long horizon,
- 13:33SPEAKER_01: alongside a separate immediate strong buy and keep for dividends rating.
- 13:37SPEAKER_00: Okay, let's unpack the dividends because reading a percentage yield off a chart is,
- 13:41SPEAKER_00: you know, very different from actual cash handing an account.
- 13:44SPEAKER_01: Very true.
- 13:45SPEAKER_01: So GSK pays dividends quarterly.
- 13:48SPEAKER_01: The 8 October payment is already paid and therefore excluded from any future return maths.
- 13:53SPEAKER_01: The only currently declared future dividend is the 17 pence payable on 7 January 2027.
- 13:59SPEAKER_00: But investors project out further than that, right?
- 14:02SPEAKER_00: Like if we assume a flat seasonal expectation for the full year 2026 of 70 pence,
- 14:08SPEAKER_00: meaning a repeating pattern of 17 pence in January,
- 14:10SPEAKER_00: 19 in April,
- 14:11SPEAKER_00: 17 in July and 17 in October, what does that actually look like in hand?
- 14:16SPEAKER_01: Under that flat seasonal assumption,
- 14:18SPEAKER_01: there are three future payments totaling 53 pence before
- 14:21SPEAKER_01: the September 2027 endpoint.
- 14:23SPEAKER_01: Looking further out, there are 19 payments totaling 3.33 pounds before the 2031 endpoint.
- 14:30SPEAKER_01: If you add this gross cash to the share values,
- 14:32SPEAKER_01: the cumulative gross cash plus price gains jump to 13.64% and 60.81%.
- 14:37SPEAKER_00: And I want to be crystal clear for you listening,
- 14:42SPEAKER_00: that is before taxes and fees and assumes absolutely no reinvestment
- 14:46SPEAKER_00: of those dividends.
- 14:47SPEAKER_00: It is fundamentally different from a platform rating
- 14:49SPEAKER_00: that calculates historical net yield and constant reinvestment.
- 14:53SPEAKER_01: Exactly.
- 14:54SPEAKER_00: Now, the research provides qualitative conditional cases.
- 14:58SPEAKER_00: What has to happen for the bull case to play out?
- 15:01SPEAKER_01: The bull case requires long acting HIV conversions,
- 15:04SPEAKER_01: new oncology launches and hepatitis B commercialization to grow fast enough
- 15:09SPEAKER_01: to replace older patented profits.
- 15:11SPEAKER_01: It assumes restructuring improves research productivity so that
- 15:15SPEAKER_01: the acquisition debt is comfortably absorbed.
- 15:17SPEAKER_00: And if the runner drops the baton like the bear case.
- 15:21SPEAKER_01: The bear case is the loss of oral HIV exclusivity between 2028 and 2030.
- 15:26SPEAKER_01: Brutal payer price pressure and trial failures colliding head on
- 15:30SPEAKER_01: with mounting interest and cash restructuring costs.
- 15:33SPEAKER_00: Ouch.
- 15:34SPEAKER_00: And it is worth reminding everyone the published lower and upper numerical bounds in
- 15:39SPEAKER_00: the research reflect the minimum and maximum advisor base paths.
- 15:44SPEAKER_00: They are not independent downside stress cases, nor are they a guaranteed floor.
- 15:49SPEAKER_01: Right.
- 15:50SPEAKER_01: Having 14 positive base paths does not rule out the possibility of a loss.
- 15:55SPEAKER_00: Which naturally brings us to the four quadrants.
- 15:57SPEAKER_00: We have ordinary positive drivers like specialty oncology and adult vaccine demand
- 16:03SPEAKER_00: against ordinary frictions like payer pricing and
- 16:07SPEAKER_00: the looming oral dolotegravir patent expiry.
- 16:10SPEAKER_00: But what are the extreme tales?
- 16:12SPEAKER_01: The downside tales would be a major late stage clinical failure or an earlier
- 16:17SPEAKER_01: than expected generic entry if adverse patent litigation goes against them.
- 16:21SPEAKER_00: And the upside?
- 16:22SPEAKER_01: The upside tales revolve around unexpectedly strong commercial uptake
- 16:26SPEAKER_01: for hepatitis B or successful longer acting HIV development.
- 16:30SPEAKER_00: OK, let's talk about hepatitis B,
- 16:31SPEAKER_00: because the drug Hibzago is a fascinating case study in how timelines work.
- 16:36SPEAKER_00: It received its first global approval in Japan on 24 August,
- 16:40SPEAKER_00: which was already known by the September research cutoff.
- 16:43SPEAKER_00: But the U.S. approval followed on 20 October, which is entirely new information.
- 16:47SPEAKER_01: And that U.S. approval shifts the entire narrative.
- 16:50SPEAKER_01: The upside is now all about commercial uptick.
- 16:53SPEAKER_01: We are no longer waiting on a future U.S. approval.
- 16:56SPEAKER_01: We aren't claiming it's a universal cure.
- 16:58SPEAKER_00: It hit a functional cure trial endpoint for eligible patients, right?
- 17:02SPEAKER_01: Exactly.
- 17:03SPEAKER_01: The only question now is how well can they sell it in the real world?
- 17:06SPEAKER_00: Because clinical success does not always equal commercial cash.
- 17:10SPEAKER_00: Speaking of which,
- 17:11SPEAKER_00: if margins are holding steady and they are successfully buying future revenue,
- 17:15SPEAKER_00: why is the market pricing this so defensively?
- 17:17SPEAKER_00: Like what is Wall Street missing in this alpha gap?
- 17:20SPEAKER_01: The proposed alpha-gap hypothesis suggests the market may be over-discounting
- 17:24SPEAKER_01: the eventual loss of those oral HIV patents,
- 17:27SPEAKER_01: while simultaneously under-crediting the replacement therapies and
- 17:31SPEAKER_01: the heavily funded research engine.
- 17:33SPEAKER_00: But the research engine is powered by correlated AI perspectives, right?
- 17:36SPEAKER_00: We are looking at 14 AI contributions across nine frameworks and three model versions.
- 17:41SPEAKER_01: Yes, and 12 of them share Gemini.
- 17:44SPEAKER_01: This means they are correlated AI interpretations, not 14 wildly independent human analysts.
- 17:50SPEAKER_00: Right.
- 17:50SPEAKER_01: The highest weight perspective,
- 17:51SPEAKER_01: the universal investor GPT using Astra,
- 17:54SPEAKER_01: anchors purely on disciplined reinvestment and cash generation.
- 17:58SPEAKER_01: It does not require peer re-rating to find value.
- 18:01SPEAKER_00: But the Claude perspective highlights something that explains
- 18:03SPEAKER_00: the market's fear perfectly, a staggered funding calendar.
- 18:07SPEAKER_01: This is the crux of the timing risk.
- 18:09SPEAKER_01: The financing pressure and
- 18:10SPEAKER_01: the near-term restructuring cash effects are hitting first right now in 2026
- 18:15SPEAKER_01: and 2027.
- 18:16SPEAKER_01: That happens before the oral HIV patent erosion hits later in 2028 to 2030.
- 18:21SPEAKER_01: I see.
- 18:23SPEAKER_01: Throw in the fact that conditional U.S. tariff relief expires on 20 January, 2029.
- 18:28SPEAKER_01: And you see these are sequential rolling pressures, not simultaneous ones.
- 18:32SPEAKER_00: So the new runner needs the baton, the massive cash funding right now in 2026.
- 18:38SPEAKER_00: But the old runner doesn't hit a wall until 2028.
- 18:41SPEAKER_00: The pressure arrives first.
- 18:43SPEAKER_00: The replacement cash is needed later.
- 18:45SPEAKER_00: Do the models actually reflect that upcoming wall?
- 18:48SPEAKER_01: They do, yes.
- 18:50SPEAKER_01: The quarterly path in the model retains a genuine 1.33% quarter-to-quarter downstep
- 18:56SPEAKER_01: on 18 June 2028 to account for this.
- 18:59SPEAKER_00: Wow, okay.
- 19:00SPEAKER_01: And for actual upcoming events,
- 19:02SPEAKER_01: we are watching for a potential November decision on the Laticib,
- 19:05SPEAKER_01: their targeted medicine for ALK-positive lung cancer.
- 19:08SPEAKER_01: Note that is a decision date, not necessarily an approval.
- 19:12SPEAKER_01: We also have future full-year results slated for 3 February 2027.
- 19:17SPEAKER_00: What about the trial pipeline?
- 19:19SPEAKER_00: Is the engine actually running?
- 19:21SPEAKER_01: 18 phase three studies are started with four more on track by year end.
- 19:25SPEAKER_01: That means the full year target of 22 remains totally intact.
- 19:29SPEAKER_01: It represents steady progress toward the goal, not a reduction.
- 19:32SPEAKER_01: But remember, trial starting does not mean trial succeeding.
- 19:35SPEAKER_00: Especially in HIV.
- 19:37SPEAKER_00: What are we seeing there?
- 19:38SPEAKER_01: Well, the four-month HIV prevention data remains under analysis.
- 19:42SPEAKER_01: There is a separate Quattro treatment study using the same formulation.
- 19:46SPEAKER_01: Management is confident, but, you know, confidence is not a proven scientific resolution yet.
- 19:52SPEAKER_00: Cracking the timeline of business changes here is dizzying.
- 19:55SPEAKER_00: I mean,
- 19:55SPEAKER_00: the Newfoundland agreement on 9 June was already known by the 5 July baseline,
- 20:00SPEAKER_00: but its actual completion on 15 July,
- 20:03SPEAKER_00: the DETRO approval on 22 July,
- 20:05SPEAKER_00: and the Q2 restructuring on 28 July were all new business changes informing
- 20:10SPEAKER_00: the September research.
- 20:11SPEAKER_00: Then October Q3 added later actual evidence.
- 20:15SPEAKER_01: It is a massive, relentless influx of capital commitments.
- 20:20SPEAKER_00: It reminds me qualitatively of our last covered stock, Proximus.
- 20:25SPEAKER_00: Telecom operators invest billions in network upgrades
- 20:27SPEAKER_00: while simultaneously serving their existing customers on the old network.
- 20:31SPEAKER_01: That's a great comparison.
- 20:32SPEAKER_00: Right.
- 20:33SPEAKER_00: GSK is doing the exact same thing,
- 20:35SPEAKER_00: investing massively in scientific research and acquisitions
- 20:38SPEAKER_00: while selling existing drugs.
- 20:40SPEAKER_00: The operating profit looks healthy, but the cash remaining after securing the future is tight.
- 20:45SPEAKER_01: We see these patterns constantly.
- 20:47SPEAKER_01: It echoes Novo Nordisk,
- 20:49SPEAKER_01: where we explored massive patient demand versus payer access and retained profits.
- 20:54SPEAKER_01: It mirrors Boston Scientific regarding the delicate balance of innovation,
- 20:58SPEAKER_01: acquisition commitments, and cash.
- 21:00SPEAKER_01: And it absolutely connects to Medtronic,
- 21:02SPEAKER_01: where we looked at portfolio choices
- 21:04SPEAKER_01: and how headline per share earnings can contrast sharply
- 21:07SPEAKER_01: with continuing cash generation.
- 21:10SPEAKER_00: Okay, looking at all this sequential pressure, what breaks the thesis?
- 21:14SPEAKER_00: Like, if I'm playing devil's advocate,
- 21:16SPEAKER_00: strong growth that requires endless debt without adequate returns is just
- 21:20SPEAKER_00: a slow failure, right?
- 21:22SPEAKER_01: Exactly that.
- 21:23SPEAKER_01: Repeated weak cash conversion would invalidate this.
- 21:27SPEAKER_01: Meaningful trial setbacks or an inability to replace those oral HIV economics before
- 21:32SPEAKER_01: the debt comes due.
- 21:33SPEAKER_01: Furthermore, legal risk in pharma is never completely over and dividends are never guaranteed.
- 21:39SPEAKER_00: So to synthesize this deep dive,
- 21:42SPEAKER_00: we are looking at a highly attractive dated valuation and
- 21:45SPEAKER_00: a massive portfolio replacement opportunity.
- 21:48SPEAKER_00: But it is balanced on a knife's edge against the immense cost and
- 21:52SPEAKER_00: the grueling staggered timing of producing new cash flows.
- 21:56SPEAKER_00: Will the old drugs fund the new ones in time?
- 22:00SPEAKER_01: That's the billion pound question.
- 22:02SPEAKER_00: For the bigger picture,
- 22:03SPEAKER_00: visit iPulse AI to explore our complete rankings of covered assets,
- 22:07SPEAKER_00: discover the strongest buys,
- 22:09SPEAKER_00: and see the research behind the ratings all in one place.
- 22:12SPEAKER_01: Primary research conducted through the iPulse AI platform by Future Edge Group.
- 22:17SPEAKER_00: If you found this breakdown valuable, please like, comment, and subscribe.
- 22:20SPEAKER_01: Absolutely.
- 22:21SPEAKER_00: We are publishing a new podcast every day of the week except Thursday.
- 22:25SPEAKER_00: Stay tuned for the next podcast on RxSite.
- 22:28SPEAKER_01: Looking forward to it.
- 22:30SPEAKER_00: The economics of adjustable intraocular lenses are absolutely fascinating.
- 22:34SPEAKER_00: But until then, as you evaluate GSK, keep your eye on that baton pass.
- 22:40SPEAKER_00: Because in biopharma, dropping the cash flow baton means you lose the race.